Chapter 6 200 Supplementary Table S8. Multivariable linear mixed-effect model of determinants of higher total illness perception questionnaire (B-IPQ) scores over time (month 1, 6 and 12 since illness onset) 95% CI Coef. Lower limit Upper limit p-value Time since illness onset, months 0.001 1 Ref. 6 -5.64 -9.07 -2.22 12 -5.82 -9.22 -2.43 Trajectory group <0.001 Trajectory 1 Ref. Trajectory 2 6.73 2.64 10.81 Trajectory 3 17.67 12.70 22.64 Trajectory 4 19.15 12.95 25.35 Age, years (per 10 year increase) 0.74 -0.14 1.63 0.130 Sex 0.749 Male Ref. Female 0.63 -2.06 3.32 Timing of infection <0.001 First wave Ref. Subsequent waves -7.40 -10.27 -4.54 Initial COVID-19 severity <0.001 Mild Ref. Moderate 6.26 3.27 9.26 Severe/critical 6.51 2.80 10.22 According to Likelihood Ratio Tests, BMI category did not lead to a significantly better fit and was therefore excluded. Timing of SARS-CoV-2 infection defined as: first wave (up to 1 June 2020) and subsequent waves (on or after 1 June 2020). Clinical severity defined as: mild as having an RR <20/min and SpO2on room air >94% at both D0 and D7; moderate disease as having a RR 20–30/minutes, SpO2 90–94% and/or receiving oxygen therapy at D0 or D7; severe disease as having a RR >30/minutes or SpO2 <90% at D0 or D7; critical disease as requiring ICU admission. Long COVID symptoms were defined as those developing within 1 month of overall illness onset, in order to exclude sporadic symptoms that were less likely to be attributed to the consequences of COVID-19. Trajectory group membership was based on the maximum a posteriori probability of belonging to that group. * Group-based trajectory based on symptomatology over a two-year period since illness onset.
RkJQdWJsaXNoZXIy MTk4NDMw